Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:12:43.473Z.
Calculation as of: 2026-10-06T19:12:43.473Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$560.59M
Price/FCF Ratio
N/A
TTM Avg
67.09
3Y Avg
65.49
5Y Avg
24.64
Market Cap
$542.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$543.16M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$578.98M
Price/FCF Ratio
N/A
TTM Avg
16.85
3Y Avg
16.85
5Y Avg
16.85
Market Cap
$582.25M
Price/FCF Ratio
N/A
TTM Avg
59.55
3Y Avg
26.45
5Y Avg
31.22
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $560.59M | N/A | 67.09 | 65.49 | 24.64 |
| CorMedix Inc. (CRMD)vs › | $568.78M | 2.27 | 8.28 | 11.19 | 11.19 |
| Shattuck Labs, Inc. (STTK)vs › | $546.10M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $542.62M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $543.16M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.98M | N/A | 16.85 | 16.85 | 16.85 |
| Fulgent Genetics, Inc. (FLGT)vs › | $582.25M | N/A | 59.55 | 26.45 | 31.22 |
| ProKidney Corp. (PROK)vs › | $534.37M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $583.30M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
